此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Improving Medication Compliance and Smoking Cessation Treatment Outcomes for African American Smokers

2012年6月27日 更新者:Nikki Nollen, PhD, MA
Little is known about the support needed to improve compliance with Chantix for smoking cessation. This is a two arm pilot study of African American smokers to provide varying levels of side effect management and compliance support during a 12 week treatment period. The primary aim of the study is to estimate the effect of induction support compared to standard care in increasing compliance with Chantix at month 3

研究概览

研究类型

介入性

注册 (实际的)

72

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Kansas
      • Kansas City、Kansas、美国、66160
        • University of Kansas Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  • African American
  • 18-75 years of age
  • Smoke more than 10 cigarettes per day
  • Have a functioning telephone number
  • Be interested in quitting smoking
  • Be willing to take 3 months of Chantix
  • Be willing to complete all study visits

Exclusion Criteria:

  • Renal impairment
  • Evidence or history of clinically significant allergic reactions to Chantix
  • Cardiovascular event in the past month
  • History of alcohol or drug abuse/dependency in the past year
  • Major depressive disorder in the last year requiring treatment
  • History of panic disorder
  • Psychosis, bipolar or eating disorder
  • Use of antidepressants, antipsychotics, mood stabilizers/anticonvulsants or naltrexone
  • Use of tobacco products other than cigarettes
  • Use of nicotine replacement therapy, bupropion, clonidine or nortriptyline in the month prior to enrollment
  • Prior use of Chantix
  • Women who are pregnant, contemplating getting pregnant or breastfeeding
  • Plans to move from Kansas City during the 3 month treatment phase
  • Another household member enrolled in the study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:1
Chantix for 3 months and Standard Counseling
Chantix 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7, and 1 mg twice daily on day 8 through end of treatment at month 3
其他名称:
  • 伐尼克兰
Visit with counselor on Day 8 to develop a plan to quit smoking. Discuss strategies to quit, risks of continued smoking and discuss strategies for coping with withdrawal and craving.
实验性的:2
Chantix for 3 months and Adherence Counseling
Chantix 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7, and 1 mg twice daily on day 8 through end of treatment at month 3
其他名称:
  • 伐尼克兰
Visit with counselor on Day 8 to develop a plan to quit smoking. Discuss strategies to quit, risks of continued smoking and discuss strategies for coping with withdrawal and craving.
Induction Support counseling on days 8, 12, 20 and months 1 and 2. Adherence counseling based on the Information-Motivation-Behavioral Skills model of adherence behavioral change.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percent Compliance With Chantix
大体时间:Months 1, 2, 3
Compliance with Chantix calculated as the total doses taken over the total number of doses prescribed. Adherence was measured by pill counts. Measurements taken during monthly medication refill visits. There was no specific predetermined cutoff number on the scale which determined non-compliance. All results from compliance calculations are included in the table.
Months 1, 2, 3

次要结果测量

结果测量
措施说明
大体时间
Cotinine Verified 7 Day Point Prevalence Smoking Abstinence
大体时间:Month 3
Smoking cessation verified by salivary cotinine (COT). A COT of <20 ng/ml indicated smoking abstinence.
Month 3
Carbon Monoxide-verified Abstinence
大体时间:Month 1
Carbon monoxide-verified abstinence determined as a measure of <10 ppm (parts per million). Less than 2ppm CO found in healthy non-smokers.
Month 1
Carbon Monoxide-verified Abstinence
大体时间:Month 2
Carbon monoxide-verified abstinence determined as a measure of <10 ppm (parts per million). Less than 2ppm CO found in healthy non-smokers.
Month 2

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Nicole Nollen, PhD、University of Kansas Medical Center

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2008年10月1日

初级完成 (实际的)

2010年3月1日

研究完成 (实际的)

2010年3月1日

研究注册日期

首次提交

2008年10月27日

首先提交符合 QC 标准的

2008年10月28日

首次发布 (估计)

2008年10月29日

研究记录更新

最后更新发布 (估计)

2012年7月11日

上次提交的符合 QC 标准的更新

2012年6月27日

最后验证

2012年6月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

Chantix的临床试验

3
订阅